David Altshuler - 14 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
14 Feb 2022
Transactions value $
-$567,057
Form type
4
Date filed
16 Feb 2022, 15:05
Previous filing
14 Feb 2022
Next filing
22 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$567K -2.44K -4.08% $232.02 57.4K 14 Feb 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $232.02 (range $231.82 to $232.60).
F3 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.